Results 271 to 280 of about 892,099 (304)

Immune Checkpoint Inhibitors in Gliomas

Current Oncology Reports, 2017
Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan, Amy B, Heimberger, Mustafa, Khasraw   +2 more
openaire   +2 more sources

Melanoma and Immune Checkpoint Inhibitors

Current Oncology Reports, 2018
Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue, Takamichi, Ito, Naoko, Wada, Maiko, Wada, Takafumi, Kadono, Hiroshi, Uchi   +5 more
openaire   +2 more sources

Immune Checkpoint Inhibitor Toxicity

Current Oncology Reports, 2018
Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire   +2 more sources

Immune checkpoint inhibitors in GBM

Journal of Neuro-Oncology, 2021
The purpose of this review is to summarize recent updates regarding immune checkpoint inhibitor therapy in GBM patients including updates in brain immunology, clinical trials, mechanisms of resistance, and biomarkers of response.PubMed was searched to identify recent relevant articles on immune checkpoint inhibitor therapy as it pertains to GBM ...
openaire   +2 more sources

Checkpoint inhibitors go viral

Nature Biotechnology, 2019
As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.
openaire   +2 more sources

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Cell, 2023
Marlies Meisel, Steven J Mullett, Stacy L Gelhaus   +2 more
exaly  

Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

Ocular Immunology and Inflammation, 2021
Madeline Yung, Edmund Tsui
exaly  

Immuno-oncology checkpoint inhibitors

Nature Biotechnology, 2022
openaire   +2 more sources

Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis

Gastroenterology, 2021
Ricardo C Ferreira, Benjamin P Fairfax, Andrew Protheroe   +2 more
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly